Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…
Positive Late-Breaking Data for Incytes First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting…
Prime Success Responds to Sinovac Biotechs False and Misleading Claims
For More Information, Visit www.SaveSinovac.comHONG KONG--(BUSINESS WIRE)--Prime Success L.P., (together with its…
LifeLabs Supports Communities Impacted by Saskatchewan Wildfires with $15,000 Donation
Toronto, ON, June 10, 2025 (GLOBE NEWSWIRE) -- In response to the…
Quantum Metal Recovery Inc. Responds to Besra Gold’s ASX Announcement, Initiates Legal Proceedings in Ontario
PENANG, Malaysia, June 6, 2025 /PRNewswire/ -- Quantum Metal Recovery Inc. (QMRI),…
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign
MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal…
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE…